Abstract | AIMS: METHODS: RESULTS: CONCLUSION: Sequential nephron blockade with either metolazone or chlorothiazide appears to be efficacious and safe in ADHF, renal dysfunction, and diuretic resistance. Given the considerable cost difference favoring oral metolazone, larger randomized studies are warranted to confirm our findings and to exclude the possibility of confounding by indication.
|
Authors | Michael P Moranville, Suji Choi, Jennifer Hogg, Allen S Anderson, Jonathan D Rich |
Journal | Cardiovascular therapeutics
(Cardiovasc Ther)
Vol. 33
Issue 2
Pg. 42-9
(Apr 2015)
ISSN: 1755-5922 [Electronic] England |
PMID | 25712736
(Publication Type: Comparative Study, Journal Article)
|
Copyright | © 2015 John Wiley & Sons Ltd. |
Chemical References |
- Sodium Chloride Symporter Inhibitors
- Sodium Potassium Chloride Symporter Inhibitors
- Chlorothiazide
- Metolazone
|
Topics |
- Acute Disease
- Administration, Intravenous
- Administration, Oral
- Aged
- Chicago
- Chlorothiazide
(administration & dosage, adverse effects, therapeutic use)
- Drug Resistance
- Drug Therapy, Combination
- Female
- Heart Failure
(diagnosis, physiopathology, therapy)
- Hospitalization
- Humans
- Length of Stay
- Male
- Metolazone
(administration & dosage, adverse effects, therapeutic use)
- Middle Aged
- Nephrons
(drug effects, physiopathology)
- Retrospective Studies
- Sodium Chloride Symporter Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Sodium Potassium Chloride Symporter Inhibitors
(adverse effects, therapeutic use)
- Time Factors
- Treatment Outcome
- Urination
(drug effects)
|